Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of ALTB-268 in Subjects With Moderately to Severely Active Ulcerative Colitis Refractory to Biologic Therapy

NCT06109441 is registered in ClinicalTrials.gov with AltruBio Inc. as lead sponsor.

NCT NCT06109441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06109441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of ALTB-268 in Subjects With Moderately to Severely Active Ulcerative Colitis Refractory to Biologic Therapy
Lead sponsor
AltruBio Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 4, 2023
Completion date
March 31, 2028
Enrollment
50 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis